NCT05808920 The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
| NCT ID | NCT05808920 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Marsden NHS Foundation Trust |
| Condition | Head and Neck Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-09-08 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-09-08 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The RESCUE study is a combined retrospective and prospective multicentre cohort study investigating the survival and functional outcomes in patients undergoing salvage surgery for recurrent, residual, and new primary head and neck squamous cell carcinoma (SCC). Additionally, the RESCUE study will contain an exploratory molecular analysis of consenting patients to assess the relationship between cancer genomics, previous radiotherapy, and recurrence in head and neck cancer.
Eligibility Criteria
Inclusion Criteria: 1. Aged over 18 2. Previous H\&N SCC treated with radiotherapy with or without chemotherapy 3. Local or regionally recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx 4. Ability to give informed consent for biological sample collection (molecular analysis study only) Exclusion Criteria: 1. Nasopharyngeal and cutaneous SCC of the H\&N 2. Thyroid, salivary gland, and non-squamous cell H\&N cancers 3. Presence of distant metastasis (M1) or surgically inoperable T4b tumours
Contact & Investigator
Vinidh Paleri
PRINCIPAL INVESTIGATOR
Royal Marsden Hospital NHS Foundation Trust
Frequently Asked Questions
Who can join the NCT05808920 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05808920 currently recruiting?
Yes, NCT05808920 is actively recruiting participants. Contact the research team at andrew.williamson2@rmh.nhs.uk for enrollment information.
Where is the NCT05808920 trial being conducted?
This trial is being conducted at Derby, United Kingdom, Edinburgh, United Kingdom, Glasgow, United Kingdom, Liverpool, United Kingdom and 5 additional locations.
Who is sponsoring the NCT05808920 clinical trial?
NCT05808920 is sponsored by Royal Marsden NHS Foundation Trust. The principal investigator is Vinidh Paleri at Royal Marsden Hospital NHS Foundation Trust. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.